Article Text

PDF
Penetrance of marked cognitive impairment in older male carriers of the FMR1 gene premutation
  1. M Sévin1,
  2. Z Kutalik2,3,
  3. S Bergman2,3,
  4. M Vercelletto1,
  5. P Renou1,
  6. E Lamy1,
  7. F J Vingerhoets4,
  8. G Di Virgilio4,
  9. P Boisseau5,
  10. S Bezieau5,
  11. L Pasquier6,
  12. J-M Rival5,
  13. J S Beckmann2,7,
  14. P Damier1,
  15. S Jacquemont7
  1. 1
    CHU Nantes, CIC0004, Service de Neurologie, Nantes, France
  2. 2
    Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
  3. 3
    Swiss Institute for Bioinformatics, Lausanne, Switzerland
  4. 4
    CHUV, Département de Neurologie, Lausanne, Switzerland
  5. 5
    CHU Nantes, Service de Génétique Médicale, Nantes 44093, France
  6. 6
    CHU Rennes, Service de Génétique Médicale, Rennes 35023, France
  7. 7
    CHUV, Service de Génétique Médicale, Lausanne, Switzerland
  1. Correspondence to Dr S Jacquemont, Service de génétique médical, CHUV, 2, ave Pierre Decker, 1011 Lausanne, Switzerland; sebastien.jacquemont{at}chuv.ch

Abstract

Background: Male carriers of the FMR1 premutation are at risk of developing the fragile X–associated tremor/ataxia syndrome (FXTAS), a newly recognised and largely under-diagnosed late onset neurodegenerative disorder. Patients affected with FXTAS primarily present with cerebellar ataxia and intention tremor. Cognitive decline has also been associated with the premutation, but the lack of data on its penetrance is a growing concern for clinicians who provide genetic counselling.

Methods: The Mattis Dementia Rating Scale (MDRS) was administered in a double blind fashion to 74 men aged 50 years or more recruited from fragile X families (35 premutation carriers and 39 intrafamilial controls) regardless of their clinical manifestation. Based on previous publications, marked cognitive impairment was defined by a score ⩽123 on the MDRS.

Results: Both logistic and survival models confirmed that in addition to age and education level, premutation size plays a significant (p<0.01 and p<0.03 for logistic and survival model, respectively) role in cognitive impairment. The estimated penetrance of marked cognitive impairment in our sample (adjusted for the mean age 63.4 years and mean education level 9.7 years) for midsize/large (70–200 CGG) and small (55–69 CGG) premutation alleles was 33.3% (relative risk (RR) 6.5; p = 0.01) and 5.9% (RR 1.15; p = 0.9) respectively. Penetrance in the control group was 5.1%.

Conclusions: Male carriers of midsize to large premutation alleles had a sixfold increased risk of developing cognitive decline and the risk increases with allele size. In addition, it was observed that cognitive impairment may precede motor symptoms. These data provide guidance for genetic counselling although larger samples are required to refine these estimates.

Statistics from Altmetric.com

Footnotes

  • Additional material is published online only at http://jmg.bmj.com/content/vol46/issue12

  • Funding PHRC BRD 04/10-G, MS was supported by the Fondation Recherche Médicale (grant DEA20050904941), SB and ZK by the Cavaglieri Foundation and the Swiss National Science Foundation (SNSF grant 3100AO-116323/1), and JSB by the SNSF grant 310000-112552/1.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.